Related Research Articles
Diabetic retinopathy, is a medical condition in which damage occurs to the retina due to diabetes. It is a leading cause of blindness in developed countries.
An angiogenesis inhibitor is a substance that inhibits the growth of new blood vessels (angiogenesis). Some angiogenesis inhibitors are endogenous and a normal part of the body's control and others are obtained exogenously through pharmaceutical drugs or diet.
Moses Judah Folkman was an American biologist and pediatric surgeon best known for his research on tumor angiogenesis, the process by which a tumor attracts blood vessels to nourish itself and sustain its existence. He founded the field of angiogenesis research, which has led to the discovery of a number of therapies based on inhibiting or stimulating neovascularization.
Neovascularization is the natural formation of new blood vessels, usually in the form of functional microvascular networks, capable of perfusion by red blood cells, that form to serve as collateral circulation in response to local poor perfusion or ischemia.
Charles Louis Schepens was a Belgian and American ophthalmologist, regarded by many in the profession as "the father of modern retinal surgery", and member of the French Resistance.
Ian Jeffrey Constable is an Australian ophthalmologist and the founder and director of the Lions Eye Institute in Perth, Western Australia. He was the Foundation Lions Professor of Ophthalmology at the University of Western Australia, and the Foundation Director of UWA's Centre for Ophthalmology and Visual Science. He is now Patron of the Lions Eye Institute.
The Champalimaud Foundation is a private biomedical research foundation. It was created according to the will of the late entrepreneur António de Sommer Champalimaud, in 2004. The complete name of the foundation honors the mother and father of the founder and is Fundação Anna de Sommer Champalimaud e Dr. Carlos Montez Champalimaud. It is located in Lisbon, Portugal.
Choroidal neovascularization (CNV) is the creation of new blood vessels in the choroid layer of the eye. Choroidal neovascularization is a common cause of neovascular degenerative maculopathy commonly exacerbated by extreme myopia, malignant myopic degeneration, or age-related developments.
Pedram Hamrah is a German-American ophthalmologist and immunologist. He obtained his M.D. from the University of Cologne, Germany.
Napoleone Ferrara is an Italian-American molecular biologist who joined University of California, San Diego Moores Cancer Center in 2013 after a career in Northern California at the biotechnology giant Genentech, where he pioneered the development of new treatments for angiogenic diseases such as cancer, age-related macular degeneration (AMD), and diabetic retinopathy. At Genentech, he discovered VEGF—and made the first anti-VEGF antibody—which suppresses growth of a variety of tumors. These findings helped lead to development of the first clinically available angiogenesis inhibitor, bevacizumab (Avastin), which prevents the growth of new blood vessels into a solid tumor and which has become part of standard treatment for a variety of cancers. Ferrara's work led also to the development of ranibizumab (Lucentis), a drug that is highly effective at preventing vision loss in intraocular neovascular disorders.
Carmen Anthony Puliafito is an American ophthalmologist and former academic administrator. From 2007 until March 2016, he was dean of the Keck School of Medicine of USC.
Julia A. Haller is an American ophthalmologist who is a Professor and Chair of the Department of Ophthalmology at Sidney Kimmel Medical College at Thomas Jefferson University. She also holds the William Tasman, M.D. Endowed Chair at Wills Eye Hospital in Philadelphia, where she is Ophthalmologist-in-Chief.
Martin Jeffrey Steinbach was an American vision researcher who spent most of his career in Canada. He was Distinguished Research Professor Emeritus in the Department of Psychology at York University. He received a master's degree from Connecticut College in 1965 and a Ph.D. from Massachusetts Institute of Technology (MIT) in 1968.
Joel S. Schuman, MD, FACS is Professor of Ophthalmology, the Kenneth L. Roper Endowed Chair, Vice Chair for Research Innovation, co-director of the Glaucoma Service at Wills Eye Hospital, Professor of Biomedical Engineering at Drexel University School of Biomedical Engineering, Science and Health Systems, Collaborative Community of Ophthalmic Imaging (CCOI) president, and American Glaucoma Society (AGS) Foundation advisory board chair. Prior to this he was the Elaine Langone Professor and Vice Chair for Research in the Department of Ophthalmology at NYU Langone Medical Center, NYU Grossman School of Medicine; Professor of Biomedical Engineering and Electrical & Computer Engineering at NYU Tandon School of Engineering and Professor of Neural Science in the Center for Neural Science at NYU College of Arts and Sciences. He chaired the ophthalmology department at NYU Langone Health, NYU Grossman School of Medicine 2016–2020, and was Vice Chair for Ophthalmology Research in the department 2020–2022. Prior to arriving at NYU in 2016, he was Distinguished Professor and Chairman of Ophthalmology, Eye and Ear Foundation Endowed Chair in Ophthalmology, Director of UPMC Eye Center (2003-2016) and before that was at Tufts University 1991–2003, where he was Residency Director (1991-1999) and Glaucoma and Cataract Service Chief (1991-2003). In 1998 he became Professor of Ophthalmology, and Vice Chair in 2001.
Reza Dana is the Claes H. Dohlman Professor of Ophthalmology, senior scientist and W. Clement Stone Clinical Research Scholar at Massachusetts Eye and Ear, Harvard Medical School, and director of the Harvard-Vision Clinical Scientist Development Program.
Aganirsen is a 25 mer DNA antisense oligonucleotide therapeutic inhibiting insulin receptor substrate-1 (IRS-1), which is being investigated as a topical treatment for ocular neovascularization. Aganirsen is a candidate for the treatment of ocular neovascularization in patients with front of the eye (cornea) or back of the eye (retinal) diseases, including progressive corneal neovascularization in patients with infectious keratitis and wet age related macular degeneration (AMD).
Joan Whitten Miller is a Canadian-American ophthalmologist and scientist who has made notable contributions to the treatment and understanding of eye disorders. She is credited for developing photodynamic therapy (PDT) with verteporfin (Visudyne), the first pharmacologic therapy for retinal disease. She also co-discovered the role of vascular endothelial growth factor (VEGF) in eye disease and demonstrated the therapeutic potential of VEGF inhibitors, forming the scientific basis of anti-VEGF therapy for age-related macular degeneration (AMD), diabetic retinopathy, and related conditions.
Daniel M. Albert is an American ophthalmologist, ocular cancer researcher, medical historian, and collector of rare books and ocular equipment. As of 2018, he is Professor of Ophthalmology at the Casey Eye Institute, Oregon Health & Science University.
Paul A. Sieving is a former director of the National Eye Institute, part of the U.S. National Institutes of Health. Prior to joining the NIH in 2001, he served on the faculty of the University of Michigan Medical School as the Paul R. Lichter Professor of Ophthalmic Genetics. He also was the founding director of the Center for Retinal and Macular Degeneration in the university's Department of Ophthalmology and Visual Sciences.
Sarah Coupland is an Australian-born pathologist and professor who is the George Holt Chair in Pathology at the University of Liverpool. Coupland is an active clinical scientist whose research focuses on the molecular genetics of cancers, with particular interests in uveal melanoma, conjunctival melanoma, intraocular and ocular adnexal lymphomas and CNS lymphoma. Coupland is also an NHS Honorary Consultant Histopathologist at the Royal Liverpool University Hospital. Since 2006, Coupland has been head of the Liverpool Ocular Oncology Research Group; from which she runs a multidisciplinary oncology research group focussing on Uveal melanoma, based in the Department of Molecular and Clinical Cancer Medicine at the University of Liverpool. Her research laboratory is currently located in the Institute of Translational Medicine From April 2014 to December 2019, Coupland was also Director of the North West Cancer Research Centre, @UoL. In both 2019 and 2020, Coupland was included on the 'Pathology Powerlist' on The Pathologist website.
References
- 1 2 "Announcement of Director of Research at Schepens Eye Research Institute". Newswise.com. 2012-10-29. Retrieved 2017-06-06.
- ↑ "Dr. D'Amore to helm the Howe Lab". schepens.harvard.edu. Retrieved 2017-06-07.
- ↑ "Anti-VEGF treatment". Royal National Institute for the Blind, UK. 2014-03-17. Retrieved 2017-06-06.
- ↑ Miller, Joan (March 2016). "VEGF: From Discovery to Therapy: The Champalimaud Award Lecture". Transl. Vis. Sci. Technol. 5 (2.9): 9. doi:10.1167/tvst.5.2.9. PMC 4790434 . PMID 26981331.
- ↑ "Patricia A. D'Amore - Google Scholar Citations". scholar.google.com. Retrieved 2020-03-02.
- ↑ Microvascular Research Journal Details.
{{cite book}}:|website=ignored (help) - ↑ "Editor Profiles FASEB Journal". fasebj.org. Archived from the original on 2017-06-13. Retrieved 2017-06-07.
- ↑ "5th Annual Jeffrey M. Isner, M.D. Endowed Memorial Lecture" (PDF). Archived from the original (PDF) on 2015-12-23.
- ↑ "Dr. Patricia D'Amore Delivers the Isner Endowed Memorial Lecture". schepens.harvard.edu. Retrieved 2020-03-02.
- ↑ "2014 António Champalimaud Vision Awardees". fchampalimaud.org. Archived from the original on 2014-12-10. Retrieved 2017-06-07.
- ↑ "Drs. Patricia D'Amore and Joan W. Miller Earn Top Honors from ARVO". eye.hms.harvard.edu. May 20, 2014. Retrieved 2017-06-07.
- ↑ "Newly Elected Fellows - American Academy of Arts and Sciences - 2018". amacad.org. Archived from the original on 2019-01-14. Retrieved 2019-03-28.
